SAN

87.36

-5.12%↓

MRK1

116.2

+1%↑

SHL.DE

46.58

-0.98%↓

ARGX

505.8

-1.21%↓

FRE

43.06

+1.25%↑

SAN

87.36

-5.12%↓

MRK1

116.2

+1%↑

SHL.DE

46.58

-0.98%↓

ARGX

505.8

-1.21%↓

FRE

43.06

+1.25%↑

SAN

87.36

-5.12%↓

MRK1

116.2

+1%↑

SHL.DE

46.58

-0.98%↓

ARGX

505.8

-1.21%↓

FRE

43.06

+1.25%↑

SAN

87.36

-5.12%↓

MRK1

116.2

+1%↑

SHL.DE

46.58

-0.98%↓

ARGX

505.8

-1.21%↓

FRE

43.06

+1.25%↑

SAN

87.36

-5.12%↓

MRK1

116.2

+1%↑

SHL.DE

46.58

-0.98%↓

ARGX

505.8

-1.21%↓

FRE

43.06

+1.25%↑

Search

Laboratorios Farmaceuticos Rovi SA

Fermé

SecteurSoins de santé

54.5 3.61

Résumé

Variation du prix de l'action

24h

Actuel

Min

54.25

Max

54.55

Chiffres clés

By Trading Economics

Revenu

-57M

32M

Ventes

199M

434M

P/E

Moyenne du Secteur

19.103

53.54

BPA

0.354

Rendement du dividende

1.79

Marge bénéficiaire

7.411

Employés

2,197

EBITDA

40M

138M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+42.79% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

1.79%

2.44%

Prochains Résultats

30 juil. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-737M

2.7B

Ouverture précédente

50.89

Clôture précédente

54.5

Sentiment de l'Actualité

By Acuity

50%

50%

174 / 381 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

31 mai 2025, 10:30 UTC

Actualités

Pension Funds Won't Save the Bond Market -- Heard on the Street -- WSJ

31 mai 2025, 06:30 UTC

Résultats

5 Things We've Learned From Retail Earnings -- Barrons.com

31 mai 2025, 04:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

30 mai 2025, 23:51 UTC

Acquisitions, Fusions, Rachats

Trump Raises Steel Tariffs, Saying U.S. Steel Will Remain U.S.-Controlled -- Update

30 mai 2025, 21:30 UTC

Actualités

Stocks Shrug Off Trade War to Post Best Month Since 2023 -- WSJ

30 mai 2025, 21:15 UTC

Actualités

The Score: E.l.f. Beauty, Tesla, Nvidia, and More Stocks That Defined the Week -- WSJ

30 mai 2025, 20:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Health Care Roundup: Market Talk

30 mai 2025, 20:44 UTC

Acquisitions, Fusions, Rachats

Bill Ackman Is Killing It. A New ETF Will Track His Investments. -- Barrons.com

30 mai 2025, 20:24 UTC

Actualités

Major U.S. Stock Indexes Finish About Flat; U.S.-China Trade Friction Renews -- WSJ

30 mai 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

30 mai 2025, 19:44 UTC

Market Talk

Gold Breaks 4-Month Winning Streak -- Market Talk

30 mai 2025, 19:38 UTC

Market Talk

Companies Delay or Cancel $14B In Clean-Energy Investments -- Market Talk

30 mai 2025, 19:29 UTC

Résultats
Acquisitions, Fusions, Rachats

NRG Energy and UnitedHealth Are the S&P 500's Best and Worst for May. Here's Why. -- Barrons.com

30 mai 2025, 19:14 UTC

Market Talk

Oil Settles Lower Ahead of OPEC+ Output Decision -- Market Talk

30 mai 2025, 19:05 UTC

Market Talk

U.S. Natural Gas Futures Fall Awaiting Hotter Weather -- Market Talk

30 mai 2025, 18:51 UTC

Market Talk

Canada's Retaliatory Tariffs Help Fuel Sizable Rise in Tax Revenue -- Market Talk

30 mai 2025, 18:37 UTC

Market Talk
Résultats

Costco Well Positioned for Sustainable Growth, UBS Says -- Market Talk

30 mai 2025, 18:04 UTC

Actualités

S&P 500 Falls After More Trump-China Friction -- WSJ

30 mai 2025, 17:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

30 mai 2025, 17:47 UTC

Market Talk

Time for BoC Gov. Macklem to Cut Rates, Desjardins Says -- Market Talk

30 mai 2025, 17:40 UTC

Acquisitions, Fusions, Rachats

Trump Is Praising His U.S. Steel Deal. No One Is Sure What It Means -- WSJ

30 mai 2025, 17:38 UTC

Market Talk

U.S: Oil Rig Count Falls for Fifth Straight Week -- Market Talk

30 mai 2025, 17:31 UTC

Market Talk

Costco Well Positioned to Gain Share Amid Tariffs, Baird Says -- Market Talk

30 mai 2025, 17:14 UTC

Actualités

American Consumers Are Still Gloomy on the Economy -- 3rd Update

30 mai 2025, 16:31 UTC

Résultats

Ulta Beauty Stock Is Rising. Earnings Strength Was More Than Cosmetic. -- Barrons.com

30 mai 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

30 mai 2025, 16:20 UTC

Market Talk
Acquisitions, Fusions, Rachats

Health Care Roundup: Market Talk

30 mai 2025, 16:16 UTC

Actualités

S&P 500 Falls After Trump Hits Out at China -- WSJ

30 mai 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

30 mai 2025, 16:14 UTC

Actualités

HSBC Retreats From Banking Smaller U.S. Businesses -- WSJ

Comparaison

Variation de prix

Laboratorios Farmaceuticos Rovi SA prévision

Objectif de Prix

By TipRanks

42.79% hausse

Prévisions sur 12 Mois

Moyen 77.75 EUR  42.79%

Haut 90 EUR

Bas 65.5 EUR

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

2 ratings

2

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

51.1 / N/ASupport & Résistance

Court Terme

Weak Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

Weak Bearish Evidence

Sentiment

By Acuity

174 / 381Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.